These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15367924)

  • 1. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
    Stemmelin J; Lukovic L; Salome N; Griebel G
    Neuropsychopharmacology; 2005 Jan; 30(1):35-42. PubMed ID: 15367924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.
    Salomé N; Stemmelin J; Cohen C; Griebel G
    Psychopharmacology (Berl); 2006 Aug; 187(2):237-44. PubMed ID: 16779555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
    Overstreet DH; Griebel G
    Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
    Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
    Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
    CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the vasopressin (V1b) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat.
    Claustre Y; Rouquier L; Desvignes C; Leonetti M; Montégut J; Aubin N; Allouard N; Bougault I; Oury-Donat F; Steinberg R
    Neuroscience; 2006 Sep; 141(3):1481-8. PubMed ID: 16781820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
    Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats.
    Zhou Y; Colombo G; Carai MA; Ho A; Gessa GL; Kreek MJ
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1876-83. PubMed ID: 21575018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
    Shimazaki T; Iijima M; Chaki S
    Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
    Griebel G; Stemmelin J; Gal CS; Soubrié P
    Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central V1b receptor antagonism in lactating rats: impairment of maternal care but not of maternal aggression.
    Bayerl DS; Klampfl SM; Bosch OJ
    J Neuroendocrinol; 2014 Dec; 26(12):918-26. PubMed ID: 25283607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.
    Amikishieva AV; Ilnitskaya SI; Nikolin VP; Popova NA
    Exp Oncol; 2011 Sep; 33(3):126-9. PubMed ID: 21956463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice.
    Zhou Y; Rubinstein M; Low MJ; Kreek MJ
    Alcohol Clin Exp Res; 2018 Jan; 42(1):195-205. PubMed ID: 29105118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
    Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
    Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor.
    Litvin Y; Murakami G; Pfaff DW
    Physiol Behav; 2011 Jun; 103(3-4):393-403. PubMed ID: 21397619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
    Serradeil-Le Gal C; Derick S; Brossard G; Manning M; Simiand J; Gaillard R; Griebel G; Guillon G
    Stress; 2003 Sep; 6(3):199-206. PubMed ID: 13129813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.